Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 5Stomach Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Neoplasms 2Melanoma 2Advanced Pancreatic Cancer 2Thoracic Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Squamous Cell Carcinoma of Lung 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Second Line Treatment of Gastric Cancer 1Sarcoma 1Resectable Biliary Tract Cancer 1Pathologic Complete Response 1Pancreatic Adenocarcinoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Muscle-Invasive Bladder Carcinoma 1Lung Diseases 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1

Interventions

sintilimab 1S 1 (combination) 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Gastric Cancer Peritoneal Metastases × Albumin-Bound Paclitaxel × Clear all
NCT06487715 2024-07-05

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
42 enrolled
Gastrointestinal

Gastric Cancer Peritoneal Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡